J&J and Emergent Bio collaborate on coronavirus vaccine candidate

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions Inc. are collaborating to support the manufacturing of Johnson & Johnson’s lead investigational COVID-19 vaccine candidate.

Johnson & Johnson said it hopes to supply more than one billion doses of the vaccine globally.

Under the manufacturing agreement, Johnson & Johnson plans to expand drug substance capacity related to the vaccine candidate. Emergent has agreed to provide drug substance manufacturing services with its molecule-to-market CDMO offering. Emergent may provide operations support for commercial manufacturing of Johnson & Johnson’s COVID-19 vaccine candidate, using Janssen’s AdVac and PER.C6 technologies beginning in 2021.

Johnson & Johnson has begun preparations for clinical vaccine production at its facility in Leiden, the Netherlands, and aims to start phase I human clinical studies of its vaccine candidate in September 2020. Johnson & Johnson will begin production at risk and is committed to bringing an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use.

Johnson & Johnson said it plans to useJanssen’s proven AdVac and PER.C6 technologies to develop new vaccine candidates and upscale production of the optimal vaccine candidate. The same technology was used to develop and manufacture the company’s investigational Ebola vaccine, and construct RSV and HIV vaccine candidates that are now in phase II or phase III of clinical development.

Table of Contents

YOU MAY BE INTERESTED IN

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.
In back-to-back congressional hearings earlier this week, HHS Secretary Robert F. Kennedy Jr. said that the massive staff and budget cuts over which he has presided during his nearly four months on the job as well as even bigger cuts still looming on the horizon are a part of a single plan.
Natalie Phelps, a 43-year-old mother of two, has stage 4 colorectal cancer. She has become a central figure in the controversy over the dysfunction the Trump administration’s RIFs and budget cuts have brought to NIH. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login